Western Wealth Management LLC Has $1.02 Million Stock Holdings in Zoetis Inc. (NYSE:ZTS)

Western Wealth Management LLC cut its stake in shares of Zoetis Inc. (NYSE:ZTS) by 13.9% in the 2nd quarter, according to its most recent Form 13F filing with the SEC. The fund owned 5,864 shares of the company’s stock after selling 943 shares during the period. Western Wealth Management LLC’s holdings in Zoetis were worth $1,017,000 as of its most recent filing with the SEC.

Several other large investors have also recently bought and sold shares of the stock. Webster Bank N. A. lifted its position in shares of Zoetis by 89.1% in the first quarter. Webster Bank N. A. now owns 174 shares of the company’s stock valued at $29,000 after buying an additional 82 shares during the last quarter. Private Wealth Management Group LLC acquired a new stake in shares of Zoetis in the fourth quarter valued at approximately $33,000. Gladius Capital Management LP acquired a new stake in shares of Zoetis in the fourth quarter valued at approximately $40,000. Neo Ivy Capital Management acquired a new stake in shares of Zoetis in the fourth quarter valued at approximately $40,000. Finally, LRI Investments LLC acquired a new stake in shares of Zoetis in the first quarter valued at approximately $43,000. 92.80% of the stock is owned by institutional investors and hedge funds.

Zoetis Price Performance

Zoetis stock traded down $0.62 during mid-day trading on Monday, reaching $183.09. 296,264 shares of the company were exchanged, compared to its average volume of 2,743,928. The company has a fifty day simple moving average of $177.78 and a 200-day simple moving average of $175.12. Zoetis Inc. has a 12 month low of $144.80 and a 12 month high of $201.92. The company has a debt-to-equity ratio of 1.32, a current ratio of 3.45 and a quick ratio of 2.09. The firm has a market cap of $83.54 billion, a PE ratio of 35.40, a PEG ratio of 2.81 and a beta of 0.86.

Zoetis (NYSE:ZTS) last issued its quarterly earnings results on Tuesday, August 6th. The company reported $1.56 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.49 by $0.07. Zoetis had a return on equity of 50.67% and a net margin of 26.29%. The company had revenue of $2.36 billion for the quarter, compared to analyst estimates of $2.31 billion. During the same quarter last year, the company posted $1.41 EPS. The company’s revenue for the quarter was up 8.3% compared to the same quarter last year. As a group, equities research analysts expect that Zoetis Inc. will post 5.84 earnings per share for the current fiscal year.

Zoetis Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Wednesday, September 4th. Stockholders of record on Thursday, July 18th will be paid a $0.432 dividend. The ex-dividend date of this dividend is Thursday, July 18th. This represents a $1.73 annualized dividend and a dividend yield of 0.94%. Zoetis’s payout ratio is 33.14%.

Wall Street Analyst Weigh In

Several research firms recently weighed in on ZTS. Argus raised Zoetis to a “strong-buy” rating in a report on Friday, August 9th. The Goldman Sachs Group dropped their price target on Zoetis from $223.00 to $196.00 and set a “buy” rating for the company in a report on Monday, May 6th. BTIG Research lifted their price target on Zoetis from $220.00 to $225.00 and gave the stock a “buy” rating in a report on Monday, August 12th. Piper Sandler lifted their price target on Zoetis from $195.00 to $210.00 and gave the stock an “overweight” rating in a report on Wednesday, August 14th. Finally, Barclays dropped their price target on Zoetis from $260.00 to $230.00 and set an “overweight” rating for the company in a report on Tuesday, April 23rd. Nine analysts have rated the stock with a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat.com, Zoetis presently has an average rating of “Buy” and an average price target of $217.11.

About Zoetis

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.